Goodnites Wart Remover Bandaid

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The recommended dosage is to administer the treatment every 48 hours as needed. This regimen may be continued for a maximum duration of up to 12 weeks. Healthcare professionals should assess the patient's response to therapy and adjust the frequency of administration accordingly within the specified time frame.

Contraindications

Use is contraindicated in the following situations:

Application on irritated, infected, or reddened skin is prohibited due to the potential for exacerbating the condition. The product should not be applied to genital warts or warts located on the face, as these areas may be sensitive and require specialized treatment.

Patients with diabetes or poor blood circulation should avoid use, as these conditions may increase the risk of adverse effects. Additionally, the product must not be used near the eyes or mucous membranes to prevent irritation or injury.

Warnings and Precautions

This product is intended for external use only. In the event of accidental ingestion, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

It is contraindicated to apply this product on irritated, infected, or reddened skin. Additionally, it should not be used on genital warts or warts located on the face. Patients with diabetes or those who exhibit poor blood circulation should refrain from using this product due to potential complications.

Healthcare professionals should advise patients to discontinue use and seek medical advice if any of the following occur: worsening of the condition, development of excessive irritation, or the emergence of unexpected side effects.

Care should be taken to avoid application near the eyes or mucous membranes, as this may lead to adverse reactions. While mild irritation may be a common occurrence, any excessive irritation warrants immediate cessation of use and consultation with a healthcare provider.

Side Effects

Patients using this product should be aware that it is intended for external use only. In clinical practice, there have been reports of adverse reactions that necessitate caution.

Common adverse reactions include worsening of the condition being treated, excessive irritation at the application site, and the occurrence of unexpected side effects. If any of these reactions are experienced, it is advised that patients discontinue use and consult a healthcare professional.

Monitoring for these adverse reactions is essential to ensure patient safety and the effective use of the product.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Goodnites Wart Remover Bandaid (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this medication for external purposes only. It is contraindicated for application on irritated, infected, or reddened skin, as well as on genital warts or warts located on the face. Additionally, this medication should not be used in children with diabetes or poor blood circulation.

In the event of excessive irritation, use should be discontinued, and a healthcare professional should be consulted. If the medication is ingested, immediate medical assistance or contact with a Poison Control Center is advised. The treatment may be repeated every 48 hours as needed, for a maximum duration of 12 weeks.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

There is no specific information regarding the use of Goodnites Wart Remover Bandaid (salicylic acid patch) during pregnancy. The drug insert does not provide safety concerns, dosage modifications, or special precautions for pregnant patients. Therefore, healthcare professionals should exercise caution when considering the use of this product in pregnant women, as the potential risks to fetal outcomes are not well characterized. It is advisable to weigh the benefits against any unknown risks when treating women of childbearing potential.

Lactation

There is no specific information regarding nursing mothers or lactation considerations provided in the drug insert for Goodnites Wart Remover Bandaid. Therefore, the effects on lactating mothers and breastfed infants are not established. Healthcare professionals should exercise caution and consider the potential risks versus benefits when recommending this product to lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective treatment and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

Postmarketing experience has indicated that some users may report mild irritation associated with the use of the product. In instances where excessive irritation occurs, it is advised to discontinue use and consult a healthcare professional. Additionally, there have been reports of worsening conditions and the development of excessive irritation. Users have also experienced unexpected side effects, which should be monitored closely.

Patient Counseling

Healthcare providers should advise patients that if the medication is swallowed, it is crucial to seek medical help or contact a Poison Control Center immediately. This information is essential for ensuring patient safety and prompt action in case of accidental ingestion.

Storage and Handling

The product is supplied in configurations that include specific NDC numbers. It should be stored at room temperature, ensuring that it is protected from light exposure. Freezing the product is not permitted, as it may compromise its integrity. Additionally, once opened, the product must be discarded to maintain safety and efficacy.

Additional Clinical Information

The product is administered topically and may be repeated every 48 hours as needed for a duration of up to 12 weeks. Clinicians should advise patients that the product is for external use only and should not be applied to irritated, infected, or reddened skin. It is contraindicated for use on genital warts or warts on the face, and patients with diabetes or poor blood circulation should avoid its use.

Patients are cautioned against applying the product near the eyes or mucous membranes. Mild irritation may occur; however, if excessive irritation develops, patients should discontinue use and consult a healthcare professional. In cases where the condition worsens, unexpected side effects arise, or if the product is swallowed, immediate medical assistance or contact with a Poison Control Center is recommended.

Drug Information (PDF)

This file contains official product information for Goodnites Wart Remover Bandaid, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)